Two issues that always seem to throw a wrench into sponsor/CROs relationships are changes to staffing and pricing. Protocol changes can disrupt trials for CROs and cause price increases for sponsors. Staffing changes can create new learning curves, delay trials, and cause sponsors to feel they were misled. Are penalties an easy way to fix both?
DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM, announced recently that it has signed an agreement with venture capital funded DecImmune Therapeutics of Cambridge, Massachusetts, USA.
Piramal Enterprises’ diagnostic division recently announced the launch of “QDx Instacheck” Right-here-Right-now.
INC Research, LLC, a therapeutically focused global clinical research organization (CRO) with a Trusted Process® for delivering reliable results, today announced James Taylor has joined the Company as Vice President, Clinical Development. Mr. Taylor joins INC Research from Pfizer, where he served most recently as Vice President, Global Clinical Trial management. In his new role, Mr. Taylor will serve as the primary liaison to biopharmaceutical customers, vendors and investigative sites for the Company's General Medicine Business Unit.
PharmaMar, a Spanish biopharmaceutical company, has selected Medidata Solutions (NASDAQ: MDSO) for its industry-leading electronic data capture (EDC) and clinical data management (CDM), safety data capture and reporting, and medical coding solutions. A member of the Zeltia Group and a leader in the development of antitumor drugs of marine origin, PharmaMar said the company’s investment in the Medidata Clinical Cloud™ will efficiently streamline its clinical trial processes in its mission to deliver drugs that treat cancer and rare ("orphan") diseases.
Doctors currently struggle to determine whether a breast tumor is likely to shift into an aggressive, life-threatening mode—an issue with profound implications for treatment.
Metabolomic screening of fasting plasma from nondiabetic subjects identified alpha-hydroxybutyrate (AHB) and linoleoyl-glycerophosphocholine (L-GPC) as joint markers of insulin resistance (IR) and glucose intolerance.
In oncology, there are many imaging endpoints based on the assessment of tumor size or function. These endpoints include disease-free survival, objective response rate, time to progression, progression-free survival and time to treatment failure.